Navigation Links
Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
Date:9/2/2008

to less than 15 minutes as we gain experience," adds Dr. Lagerwaard. "In these treatments the 'delivery' time was just 210 seconds per session." By comparison, conventional stereotactic treatment of three brain metastases using multiple dynamic conformal arcs takes more than 50 minutes from first beam on to last beam off, according to Dr. Lagerwaard.

At MIMA, Dr. Todd Scarbrough and his team treated a 77-year-old man with a history of small-cell lung cancer who had recently developed a brain metastasis. "Given his smoking and lung cancer history he was not considered a candidate for conventional neurosurgery," says Dr. Scarbrough. "We felt fast, non-invasive radiosurgery would be easier on this patient."

Joseph Ting, PhD, medical physicist, compared a RapidArc radiosurgery treatment plan with a non-coplanar IMRT plan using 14 stationary beams, which is how this patient would have been treated prior to RapidArc's availability.

"We were delighted to see that the RapidArc plan actually conformed the dose more closely to the size, shape and location of the tumor and could be delivered in three minutes instead of the 40 minutes needed for the 14-beam plan," Scarbrough said. The treatment was completed in four sessions over a four-day period.

Dr. Scarbrough adds, "Our plan is to use RapidArc any time the treatment plan gives us a dose distribution that is equal to or better than what we can get with standard IMRT, because RapidArc is so much faster. And that's much better for our patients."

In the August 15, 2008, issue of Clinical Cancer Research, (published online August 12) researchers from the University of Chicago Medical Center report that targeted radiation therapy had completely controlled all signs of cancer in 21 percent of patients who had five or fewer sites of metastatic disease.

Treatment planning analyses show that RapidArc matches or exceeds the precision of conventional IMRT systems and spares more of the healthy
'/>"/>

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
3. NIH grants $750,000 to develop device to determine temperature of neonates brain
4. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
5. Scientists create colorful brainbow images of the nervous system
6. Mouse Brain or Impressionist Painting?
7. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
8. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
9. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
10. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
11. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... on the current state of the Papain industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) filed a ... for the D.C. Circuit challenging the FAA’s Interpretation of the ... on June 25, 2014. , The AMA believes that ... intent of the FAA Modernization and Reform Act of 2012, ... new rules or regulations regarding model aircraft that are operated ...
(Date:8/22/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... 30, 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have ... June 30, , Six-months ended June 30, ( ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 ...
(Date:8/22/2014)... of Surrey have discovered how the receptors responsible for ... , The new study, published today in The ... in turn regulates the cycle of all cells in ... the local biological clock and its control are weakened ... in bladder physiology and ageing. , While ...
Breaking Biology Technology:Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2
... Sept. 6, 2011 The Immune Deficiency Foundation (IDF) ... continuing education (CE) course for  nurses. The goal of ... nurses by providing an educational update on primary immunodeficiency ... is the national patient organization dedicated to improving the ...
... 6, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... safety update following 17 months of post-approval use in ... Dupuytren,s contracture patients with a palpable cord.  After approximately ... U.S., there was no clinically meaningful change in the ...
... Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today ... will be branded as Oncoprex™ .   ... oncology sector in recognition of our advancing development programs.  We ... to unlock the unrealized potential of a growing list of ...
Cached Biology Technology:Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 2Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2
(Date:8/22/2014)... , August 22, 2014 ... ) has announced the addition of ... 2014-2018"  report to their offering.  ... ,Biometrics is a technology that helps ... on their physical or behavioral features. ...
(Date:8/22/2014)... RIVERSIDE, Calif. Thomson Reuters , a leading ... five researchers at the University of California, Riverside in ... brightest minds of our times." , To generate the ... (2002-2012) to identify researchers whose published work has had ... included among some 3,200 individuals who published the greatest ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... Inc. (Nasdaq: AWRE ), a leading supplier of ... to discuss the company,s operating results for the fourth quarter ... 5:00 p.m. Eastern Time. CEO Michael Tzannes and CFO Rick ... webcast by Thomson and can be accessed on the Investor ...
... the potentially fatal hepatitis C virus has banked its ... inability to infect animals other than humans and chimpanzees ... animal model for the disease. But now, in a ... online issue of Nature , Rockefeller University scientists ...
... . , Lack of sleep is a ... the day poses a very real and dangerous problem. ... at McGill University demonstrates interestingly, that sleep-wake states are ... melanin-concentrating hormone (MCH) neurons and orexin (Orx) neurons, which ...
Cached Biology News:Aware Announces Q4 and FY2008 Earnings Conference Call 2Discovery could lead to a new animal model for hepatitis C 2What happens when we sleep 2
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... measurements in an easy-to-use benchtop package. ... spectrometer (ESI-oa-TOF) concentrates the performance of ... which fits on your bench. The ... 10,000 FWHM and mass accuracy of ...
... The lower cost and reduced ... system make reference standard DNA analysis ... be used with any of SEQUENOM's ... High-Performance Genotyping (iPLEXTM Gold) , Gene ...
... jetSI-ENDO-FluoR is a tetramethylrhodamine-conjugated jetSI-ENDO ... at 580 nm), the powerful ... are used to determine the ... intracellular delivery and trafficking of ...
Biology Products: